CeriBell (NASDAQ:CBLL) CEO Xingjuan Chao Sells 39,540 Shares

Key Points

• CeriBell CEO Xingjuan Chao sold 39,540 shares at an average price of $24.61, generating approximately $973,079. Following the transaction, Chao retained 767,191 shares, reducing the position by 4.9%.
• CeriBell shares rose 0.6% to $24.72, near their 12-month high of $25.33. The company reported quarterly revenue of $28.10 million but missed earnings expectations, posting an adjusted loss of $0.51 per share.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and a $24.40 price target, although ratings range from “Strong Buy” to “Sell.” Several institutional investors also increased or initiated positions in the second quarter.

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CEO Xingjuan Chao sold 39,540 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $24.61, for a total transaction of $973,079.40. Following the completion of the sale, the chief executive officer owned 767,191 shares of the company's stock, valued at approximately $18,880,570.51. The trade was a 4.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Xingjuan Chao also recently made the following trade(s):

• On Friday, August 21st, Xingjuan Chao sold 6,068 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total transaction of $145,753.36.
• On Wednesday, August 19th, Xingjuan Chao sold 31,415 shares of CeriBell stock. The stock was sold at an average price of $25.03, for a total value of $786,317.45.
• On Tuesday, August 18th, Xingjuan Chao sold 2,199 shares of CeriBell stock. The shares were sold at an average price of $25.00, for a total value of $54,975.00.
• On Tuesday, July 7th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $19.90, for a total value of $776,100.00.
• On Monday, June 8th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $18.33, for a total value of $714,870.00.

CeriBell Stock Up 0.6%

Shares of CeriBell stock traded up $0.15 during trading on Friday, hitting $24.72. 220,005 shares of the stock traded hands, compared to its average volume of 343,502. The stock has a market cap of $948.70 million, a P/E ratio of -14.05 and a beta of 0.95. The company has a fifty day moving average price of $20.57 and a two-hundred day moving average price of $19.46. CeriBell, Inc. has a twelve month low of $10.85 and a twelve month high of $25.33. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. Equities research analysts predict that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Weiss Ratings cut shares of CeriBell from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, August 28th. Canaccord Genuity Group boosted their price target on CeriBell from $25.00 to $26.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. Barclays upgraded CeriBell to a "neutral" rating in a research note on Tuesday, August 18th. Raymond James Financial reissued a "strong-buy" rating and issued a $29.00 price objective on shares of CeriBell in a research note on Thursday. Finally, BTIG Research boosted their target price on CeriBell from $28.00 to $30.00 and gave the stock a "buy" rating in a report on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $24.40.

Institutional Investors Weigh In On CeriBell

Several hedge funds and other institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System lifted its position in shares of CeriBell by 409.5% during the 2nd quarter. California State Teachers Retirement System now owns 7,352 shares of the company's stock worth $143,000 after purchasing an additional 5,909 shares during the last quarter. Wellington Management Group LLP increased its position in CeriBell by 5.5% in the 2nd quarter. Wellington Management Group LLP now owns 87,698 shares of the company's stock worth $1,706,000 after buying an additional 4,572 shares during the period. Formula Growth Ltd. bought a new position in CeriBell in the 2nd quarter worth approximately $603,000. Bank of America Corp DE acquired a new position in shares of CeriBell during the second quarter worth approximately $4,619,000. Finally, PDT Partners LLC bought a new stake in shares of CeriBell in the second quarter valued at approximately $1,026,000.

About CeriBell

CeriBell Corp NASDAQ: CBLL is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source